Literature DB >> 8912167

Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis.

M E Lynch1, J D Sobel, P L Fidel.   

Abstract

The aetiology of recurrent vulvovaginal candidiasis (RVVC) caused by Candida albicans remains unclear. To adequately address the role of antifungal resistance as a potential mechanism for RVVC, a longitudinal susceptibility analysis of 177 C. albicans isolates collected from 50 C. albicans RVVC patients over a period of 3 months to 7 years was performed. Antifungals tested included clotrimazole, ketoconazole, miconazole, itraconazole and fluconazole. Results showed that all vaginal isolates were uniformly susceptible to all drugs tested and that successive isolates from individual patients did not show increased resistance to any drug despite long-term exposure to azoles. These results suggest that episodes of RVVC caused by C. albicans are rarely of ever attributable to azole antifungal resistance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912167     DOI: 10.1080/02681219680000571

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN: 0268-1218


  12 in total

1.  Effects of reproductive hormones on experimental vaginal candidiasis.

Authors:  P L Fidel; J Cutright; C Steele
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 2.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

3.  An investigation into the pathogenesis of vulvo-vaginal candidosis.

Authors:  S S El-Din; M T Reynolds; H R Ashbee; R C Barton; E G Evans
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

4.  Efficacy of D0870 treatment of experimental Candida vaginitis.

Authors:  P L Fidel; J L Cutright; J D Sobel
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  Vaginal yeasts in the era of "over the counter" antifungals.

Authors:  P P Walker; M T Reynolds; H R Ashbee; C Brown; E G Evans
Journal:  Sex Transm Infect       Date:  2000-12       Impact factor: 3.519

6.  Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans.

Authors:  M E L Consolaro; T A Albertoni; A E Svidzinski; R M Peralta; T I E Svidzinski
Journal:  Mycopathologia       Date:  2005-06       Impact factor: 2.574

7.  An unusual case of recurrent vaginal discharge: Diagnostic and therapeutic dilemma.

Authors:  Meenu Malik; Taru Garg; Ram Chander
Journal:  Indian J Sex Transm Dis AIDS       Date:  2022-06-07

Review 8.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

9.  Immune cell-mediated protection against vaginal candidiasis: evidence for a major role of vaginal CD4(+) T cells and possible participation of other local lymphocyte effectors.

Authors:  Giorgio Santoni; Maria Boccanera; Daniela Adriani; Roberta Lucciarini; Consuelo Amantini; Stefania Morrone; Antonio Cassone; Flavia De Bernardis
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

10.  Antifungal Activity of Brazilian Propolis Microparticles against Yeasts Isolated from Vulvovaginal Candidiasis.

Authors:  Kelen Fátima Dalben Dota; Marcia Edilaine Lopes Consolaro; Terezinha Inez Estivalet Svidzinski; Marcos Luciano Bruschi
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-09       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.